Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 18, 2016

View Archived Issues

Adjuvanted rabies vaccine from Yisheng Biopharma given U.S. orphan drug status for HCC

Advaxis initiates phase III trial of ADXS-11-001 in high-risk locally advanced cervical cancer

Celgene initiates first-in-human study of CC-90009 in relapsed or refractory AML

Imago initiates phase I trial of IMG-7289 in patients with advanced myeloid malignancies

Apitope regains global rights to ATX-MS-1467 from Merck KGaA

Omeros reports phase II data for OMS-721, pursuing FDA breakthrough therapy designation

Pfizer to begin shipping Inflectra next month

89Zr-Girentuximab imaging evaluated in first-in-human renal cell carcinoma study

Addex Therapeutics to initiate phase IIa trial of dipraglurant in focal cervical dystonia

European Commission approves Onivyde

Envisia Therapeutics releases interim data from ENV-515 phase II trial

EMA gives orphan drug designation to Eiger's exendin 9-39

FDA accepts NDA resubmission for sodium zirconium cyclosilicate

Positive opinion handed down in E.U. for SomaKit TOC

Responses seen with cabozantinib plus nivolumab in patients with genitourinary tumors

Sichuan Haisco Pharmaceutical patents M3 receptor antagonists and/or beta2-adrenoceptor agonists

Mutabilis discloses beta-lactamase inhibitors

Takeda Pharmaceutical describes MGL inhibitors

Jubilant Biosys develops HUNK1 inhibitors

Toray Industries presents kappa-opioid agonists

Regeneron and Teva update status of fasinumab programs

MYH7 mutations may be involved in nemaline myopathies with cardiomyopathy

PTC Therapeutics offers U.S. and E.U. regulatory update on Translarna

RYR3 variants may cause nemaline myopathy and fiber type disproportion

Zynerba offers updates on lead programs ZYN-001 and ZYN-002

Brain imaging successful with [11C]CB-184 in healthy human subjects

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...